Starshine Chemical

Starshine Pharmaceutical is a China-based biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics, primarily for oncology and autoimmune diseases. As a core research and development entity within the Shouyao Holdings group, the company has advanced a diverse pipeline of targeted inhibitors into clinical trials. Its lead programs include SY-1530, a selective Bruton's tyrosine kinase (BTK) inhibitor for B-cell malignancies, and SY-3505, a third-generation ALK inhibitor for resistant non-small cell lung cancer. Starshine utilizes its proprietary medicinal chemistry platform to address unmet medical needs in the treatment of solid tumors and hematological cancers.